Terms ending in 2037
Every in-force patent on Adimab, LLC's record whose computed term ends in 2037, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 10,053,515 | Anti-Coagulation Factor XI Antibodies In force · High confidence | Merck Sharp & Dohme LLC | In force | High confidence | |
| US 10,584,179 | Anti-Coagulation Factor XI Antibodies In force · High confidence | Merck Sharp & Dohme LLC | In force | High confidence | |
| US 12,180,299 | Multispecific Antibody Analogs Comprising a Common Light Chain, and Methods of Their Preparation and Use In force · High confidence | Adimab, LLC | In force | High confidence | |
| US 10,307,455 | Activin Type 2 Receptor Antibodies In force · High confidence | Acceleron Pharma Inc. | In force | High confidence | |
| US 11,000,565 | Methods of Increasing Muscle Mass by Administration of Activin Type 2 Receptor Antibodies In force · High confidence | Acceleron Pharma Inc. | In force | High confidence | |
| US 10,689,450 | Bcma Binding Molecules and Methods of Use Thereof In force · High confidence | Kite Pharma, Inc. | In force | High confidence | |
| US 11,059,894 | ALK7 Binding Proteins and Uses Thereof In force · High confidence | Acceleron Pharma Inc. | In force | High confidence | |
| US 11,981,738 | ALK7 Binding Proteins and Methods of Reducing ALK7 Activity Using the Same In force · High confidence | Acceleron Pharma Inc. | In force | High confidence | |
| US 10,501,547 | ALK7 Binding Proteins and Uses Thereof In force · High confidence | Acceleron Pharma Inc. | In force | High confidence | |
| US 10,684,289 | Polyclonal Mixtures of Antibodies, and Methods of Making and Using Them In force · High confidence | Adimab, LLC | In force | High confidence | |
| 5 more term ends in 2037 · Pro | |||||
10 of 15 patents shown. Soonest term end first, then patent number.
Pro members see all 15.
5 of these are in force and held by Adimab, LLC.
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.